“Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting”, J of Skin, vol. 10, no. 2, p. s730, Mar. 2026, doi: 10.25251/7mx6d484.